A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
Summary
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * ≥18 years old * Histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol. * Part 1: Participants must have experienced disease progression after treatment with, be intolerant to, or be ineligible for, or refused available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit. Part 2: depending on cohort, participants may have received or not prior treatment for the malignancy under study. * ECOG performance status score of 0 or 1. * Willingness to undergo pre- and o…
Interventions
- DrugINCA33890
INCA33890 will be administered at protocol defined dose.
- Drugbevacizumab
Bevacizumab will be administered at protocol defined dose.
- DrugFOLFIRI
FOLFIRI will be administered at protocol defined dose.
- DrugFOLFOX
FOLFOX will be administered at protocol defined dose.
- DrugCetuximab
Cetuximab will be administered at protocol defined dose.
Locations (36)
- The Angeles Clinic and Research InstituteLos Angeles, California
- Valkyrie Clinical TrialsLos Angeles, California
- Dana Farber Cancer InstituteBoston, Massachusetts
- Cancer and Hematology Centers of Western Michigan-Start MidwestGrand Rapids, Michigan
- Hackensack University Medical CenterHackensack, New Jersey
- Nyu Langone Health - Long Island HospitalMineola, New York